Product Description
Acenocoumarol is a hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. It has a role as an anticoagulant and an EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor. It is a C-nitro compound, a hydroxycoumarin and a methyl ketone.
Mechanisms of Action: Vitamin K Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Austria | Belgium | Bosnia | Bulgaria | Canada | Chile | Egypt | France | Greece | Hungary | India | Ireland | Italy | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovenia | Spain | Switzerland | Tunisia | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|